Moderna’s Covid Impact Continues
Moderna, the company responsible for developing one of the first Covid vaccines, has faced challenges in the wake of the pandemic. Despite a successful year with high stock prices and the approval of an RSV vaccine for older individuals, Moderna recently reported a decrease in full-year sales guidance. The company cited weak contracting in Europe for both its Covid and RSV vaccines as the reason for the lowered sales expectations, causing shares to drop by 20%.
One of the concerns surrounding Moderna’s future success is its ability to compete in the RSV vaccine market, especially against well-established competitors like GSK. Analysts have noted that Moderna’s RSV and flu shots have “flawed clinical profiles” compared to existing products. However, there is optimism surrounding the cancer immunotherapy that Moderna is developing in collaboration with Merck. Additionally, the company expects its RSV vaccine sales to reach $700 million by 2025.
Biogen’s Strategic Shift
In a recent earnings presentation, Biogen revealed a shift in focus away from neuroscience towards immunology research and development. The company showcased an antibody drug for kidney diseases obtained through its acquisition of Hi-Bio, signaling its interest in expanding beyond traditional neuroscience treatments. Biogen’s CEO, Chris Viehbacher, discussed the company’s M&A targets, emphasizing a move towards immunology and rare diseases.
While Biogen continues to invest in neuroscience, recent sales of its Alzheimer’s disease drug Leqembi have shown promise, with sales doubling from the previous quarter. However, uncertainties remain, particularly in Europe where regulatory challenges could impact the drug’s long-term outlook. The company is exploring opportunities for future acquisitions, with a focus on products that are ready for the market and could deliver results in the coming years.
AbbVie’s Acquisition of Cerevel
AbbVie recently closed its $8.5 billion acquisition of neuroscience company Cerevel Therapeutics, despite initial concerns raised by the FTC. The acquisition underscores AbbVie’s commitment to expanding its neuroscience portfolio in anticipation of declining sales for its blockbuster products. The deal highlights AbbVie’s interest in developing treatments for neurological disorders, with a particular focus on drugs like emraclidine for schizophrenia and tavapadon for Parkinson’s disease, which have shown promising early data.
Overall, the biotech industry continues to evolve, with companies like Moderna, Biogen, and AbbVie making strategic moves to position themselves for future success in a rapidly changing landscape. As the sector navigates ongoing challenges and opportunities, innovation and collaboration remain key drivers of progress in biotechnology.
